2. Signaling Pathways
  3. Apoptosis
  4. Survivin

Survivin

Survivin

Related Products

PDF 0.07 MB

Survivin is a member of the inhibitor of apoptosis (IAP) family. The survivin protein functions to inhibit caspase activation, thereby leading to negative regulation of apoptosis or programmed cell death. This has been shown by disruption of survivin induction pathways leading to increase in apoptosis and decrease in tumour growth. Survivin expression is highly regulated by the cell cycle and is only expressed in the G2-M phase. Survivin localizes to the mitotic spindle by interaction with tubulin during mitosis and may play a contributing role in regulating mitosis. Survivin is highly expressed in most cancers and associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival, making antisurvivin therapy an attractive cancer treatment strategy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W743417
    (-)-Norgestrel-d6
    (-)-Norgestrel-d6 is the deuterium labeled Levonorgestrel (HY-B0257). Levonorgestrel is an orally active inhibitor of progesterone (HY-N0437). Levonorgestrel has anticancer activity and can induce Apoptosis. Levonorgestrel can be used as a contraceptive and in combination with other medications. Levonorgestrel can be used in the study of osteoporosis and uterine leiomyoma.
    (-)-Norgestrel-d<sub>6</sub>
  • HY-124130
    MX106
    		Inhibitor
    MX106 is a survivin inhibitor and an analog of UC-112 (HY-12842). MX106 inhibits the expression of survivin both in vitro and in vivo. MX106 suppresses the proliferation of human melanoma cells, epidermoid carcinoma cells and colon cancer cells, and also exerts inhibitory effects on multidrug-resistant cell lines overexpressing P-glycoprotein.
    MX106
  • HY-182031
    JS04
    		Activator
    JS04 is a EGFRL858R/T790M kinase inhibitor. JS04 activates both endogenous and exogenous apoptosis (apoptosis) pathways and induces G2/M phase arrest of the cell cycle. JS04 is applicable to the research of drug-resistant non-small cell lung cancer.
    JS04
  • HY-19471
    (rac)-ZK-304709
    		Inhibitor
    (rac)-ZK-304709 is an isoform of ZK-304709 and is an orally active multi-targeted tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (CDKs), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. (rac)-ZK-304709 directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. (rac)-ZK-304709 effectively controls tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may become a potential agent for inhibiting NET.
    (rac)-ZK-304709
  • HY-N12173
    Isonanangenine B
    		Inhibitor
    Isonanangenine B (SF002-96-1) is a selective survivin inhibitor (IC50=1.6 µM). Isonanangenine B blocks the binding of key transcription factors, such as Stat3 and NF-κB, to the survivin promoter. Isonanangenine B is promising for research of cancers.
    Isonanangenine B
  • HY-177633A
    Gataparsen sodium
    		Inhibitor
    Gataparsen sodium is an antisense oligonucleotide directed against survivin mRNA with potential antitumor activity.
    Gataparsen sodium
  • HY-160438
    PBX-7011
    		Inhibitor
    PBX-7011 is an active camptothecin (HY-16560) derivative. PBX-7011 can bind to the DDX5 protein in cells, thereby inducing cell death through DDX5 protein degradation.
    PBX-7011
  • HY-N2420R
    Flavokawain A (Standard)
    		Inhibitor
    Flavokawain A is a chalcone compound and an orally active inhibitor of PRMT5 and cytochrome P450. Flavokawain A has anti-inflammatory, anti-tumor, and immunomodulatory effects. Flavokawain A can inhibit the proliferation of tumor cells and induce apoptosis. Flavokawain A can be used in the research of diseases such as bladder cancer.
    Flavokawain A (Standard)
  • HY-10194A
    Sepantronium hydrochloride
    		Inhibitor
    Sepantronium hydrochloride (YM-155 hydrochloride) is a novel survivin suppressant with an IC50 of 0.54 nM for the inhibition of survivin promoter activity.
    Sepantronium hydrochloride
  • HY-Y0396R
    N-Hydroxyphthalimide (Standard)
    		Inhibitor
    N-Hydroxyphthalimide (Standard) is the analytical standard of N-Hydroxyphthalimide (HY-Y0396). This product is intended for research and analytical applications. N-Hydroxyphthalimide is a blocking agent and catalyst. N-Hydroxyphthalimide promotes oxidation reactions by generating PINO free radicals and activating hydrogen atom transfer processes. N-Hydroxyphthalimide reduces the expression of anti-apoptotic proteins Survivin and Bcl-xL and activates caspase 9 and caspase 3. N-Hydroxyphthalimide induces Apoptosis. N-Hydroxyphthalimide inhibits the phosphorylation of mTOR (Ser2448, Ser2481) and Akt (Ser473). N-Hydroxyphthalimide has anticancer effects against breast and colon cancer.
    N-Hydroxyphthalimide (Standard)
  • HY-10194R
    Sepantronium bromide (Standard)
    		Inhibitor
    Sepantronium bromide (Standard) is the analytical standard of Sepantronium bromide (HY-10194). This product is intended for research and analytical applications. Sepantronium bromide (YM-155) is a survivin inhibitor with an IC50 of 0.54 nM.
    Sepantronium bromide (Standard)
  • HY-157136
    LFS-1107
    LFS-1107 is a reversible CRM1 inhibitor (Kd: 12.5 pM). LFS-1107 can selectively eliminate extranodal natural killer/T cell lymphoma (ENKTL) cells and can be used for cancer research.
    LFS-1107
  • HY-118447
    RO0505124
    RO0505124 is a selective CDK4 inhibitor with an IC50 of 20 nM. RO0505124 reversibly binds the ATP pocket of the kinase. RO0505124 induces G1 phase arrest in cancer cells via reduced retinoblastoma protein (Rb) phosphorylation, blocking S phase progression. RO0505124 exhibits anti-proliferative activity against various cancer cells. RO0505124 delays mitosis, induces aberrant mitosis with lagging chromosomes, driving mitotic slippage and formation of multinucleated or micronucleated cells. RO0505124 inhibits G2/M phase accumulation of survivin and borealin. RO0505124 can be used for the research of cancer.
    RO0505124
  • HY-174336
    Survivin-IN-1
    		Inhibitor
    Survivin-IN-1 (Compound II₃) is a potent Survivin (a member of the Inhibitor of Apoptosis Protein family) inhibitor with an IC50 value of 8.1 μM against human lung cancer A549 cells and 9.0 μM against breast cancer MCF-7 cells. Survivin-IN-1 reduces Survivin protein levels and induces tumor cell apoptosis. Survivin-IN-1 is promising for research of malignant tumors such as lung cancer and breast cancer.
    Survivin-IN-1
Cat. No. Product Name / Synonyms Application Reactivity